EP2462164A2 - Lung cancer biomarkers - Google Patents
Lung cancer biomarkersInfo
- Publication number
- EP2462164A2 EP2462164A2 EP10739934A EP10739934A EP2462164A2 EP 2462164 A2 EP2462164 A2 EP 2462164A2 EP 10739934 A EP10739934 A EP 10739934A EP 10739934 A EP10739934 A EP 10739934A EP 2462164 A2 EP2462164 A2 EP 2462164A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibody
- binds
- protein
- seq
- lung cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 84
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 82
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 82
- 239000000107 tumor biomarker Substances 0.000 title description 10
- 238000000034 method Methods 0.000 claims abstract description 62
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 93
- 108090000623 proteins and genes Proteins 0.000 claims description 86
- 102000004169 proteins and genes Human genes 0.000 claims description 84
- 108091007433 antigens Proteins 0.000 claims description 73
- 102000036639 antigens Human genes 0.000 claims description 73
- 239000000427 antigen Substances 0.000 claims description 71
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 45
- 230000027455 binding Effects 0.000 claims description 44
- 210000004027 cell Anatomy 0.000 claims description 35
- 239000012634 fragment Substances 0.000 claims description 35
- 210000004408 hybridoma Anatomy 0.000 claims description 32
- 102000014702 Haptoglobin Human genes 0.000 claims description 25
- 108050005077 Haptoglobin Proteins 0.000 claims description 25
- 239000003153 chemical reaction reagent Substances 0.000 claims description 19
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 claims description 16
- 108010091628 alpha 1-Antichymotrypsin Proteins 0.000 claims description 15
- 229920001184 polypeptide Polymers 0.000 claims description 15
- 101710122541 Haptoglobin-related protein Proteins 0.000 claims description 13
- 102100027772 Haptoglobin-related protein Human genes 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 102100035987 Leucine-rich alpha-2-glycoprotein Human genes 0.000 claims description 9
- 238000002493 microarray Methods 0.000 claims description 9
- 101710083711 Leucine-rich alpha-2-glycoprotein Proteins 0.000 claims description 8
- 101000737574 Homo sapiens Complement factor H Proteins 0.000 claims description 6
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 claims description 5
- 101100167771 Homo sapiens C9 gene Proteins 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 102000045512 human CFH Human genes 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 239000011325 microbead Substances 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 3
- 230000008105 immune reaction Effects 0.000 claims description 2
- 102100035432 Complement factor H Human genes 0.000 claims 2
- 101001078385 Homo sapiens Haptoglobin Proteins 0.000 claims 1
- 102000050796 human HP Human genes 0.000 claims 1
- 238000012744 immunostaining Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 32
- 201000011510 cancer Diseases 0.000 abstract description 28
- 239000000203 mixture Substances 0.000 abstract description 9
- 238000003384 imaging method Methods 0.000 abstract description 8
- 238000012544 monitoring process Methods 0.000 abstract description 7
- 238000011282 treatment Methods 0.000 abstract description 4
- 238000009509 drug development Methods 0.000 abstract description 2
- 210000002381 plasma Anatomy 0.000 description 89
- 238000012216 screening Methods 0.000 description 28
- 239000000523 sample Substances 0.000 description 27
- 238000002474 experimental method Methods 0.000 description 25
- 239000000090 biomarker Substances 0.000 description 22
- 238000002965 ELISA Methods 0.000 description 20
- 238000003556 assay Methods 0.000 description 18
- 238000005516 engineering process Methods 0.000 description 18
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 18
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 18
- 102000016550 Complement Factor H Human genes 0.000 description 17
- 108010053085 Complement Factor H Proteins 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 15
- 239000000872 buffer Substances 0.000 description 14
- 238000001262 western blot Methods 0.000 description 13
- 238000002823 phage display Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 238000004949 mass spectrometry Methods 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 10
- 238000010606 normalization Methods 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 102000003886 Glycoproteins Human genes 0.000 description 9
- 108090000288 Glycoproteins Proteins 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 108090001008 Avidin Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 108010026552 Proteome Proteins 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 102000004506 Blood Proteins Human genes 0.000 description 7
- 108010017384 Blood Proteins Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 208000009956 adenocarcinoma Diseases 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 229960002685 biotin Drugs 0.000 description 7
- 235000020958 biotin Nutrition 0.000 description 7
- 239000011616 biotin Substances 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 208000019693 Lung disease Diseases 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 102000035122 glycosylated proteins Human genes 0.000 description 5
- 108091005608 glycosylated proteins Proteins 0.000 description 5
- 208000003849 large cell carcinoma Diseases 0.000 description 5
- 239000004816 latex Substances 0.000 description 5
- 229920000126 latex Polymers 0.000 description 5
- 239000002523 lectin Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000000700 radioactive tracer Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 4
- 101001081315 Homo sapiens Haptoglobin-related protein Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000002790 cross-validation Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 102000050284 human HPR Human genes 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- -1 heat shock Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000004901 leucine-rich repeat Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000007837 multiplex assay Methods 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 101150117204 C9 gene Proteins 0.000 description 2
- 108010027644 Complement C9 Proteins 0.000 description 2
- 102100031037 Complement component C9 Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 108010088201 squamous cell carcinoma-related antigen Proteins 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012706 support-vector machine Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101710192393 Attachment protein G3P Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 101150063074 HP gene Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000783723 Homo sapiens Leucine-rich alpha-2-glycoprotein Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- 102000018317 Keratin-19 Human genes 0.000 description 1
- 238000001282 Kruskal–Wallis one-way analysis of variance Methods 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 101100431670 Rattus norvegicus Ybx3 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 208000028743 anhaptoglobinemia Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002041 carbon nanotube Substances 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FRTGEIHSCHXMTI-UHFFFAOYSA-N dimethyl octanediimidate Chemical compound COC(=N)CCCCCCC(=N)OC FRTGEIHSCHXMTI-UHFFFAOYSA-N 0.000 description 1
- LRPQMNYCTSPGCX-UHFFFAOYSA-N dimethyl pimelimidate Chemical compound COC(=N)CCCCCC(=N)OC LRPQMNYCTSPGCX-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 201000008752 progressive muscular atrophy Diseases 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000028646 regulation of complement activation Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- JJGWLCLUQNFDIS-GTSONSFRSA-M sodium;1-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 JJGWLCLUQNFDIS-GTSONSFRSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
Definitions
- the present invention relates to compositions and methods for detecting, managing or monitoring cancer.
- the invention also relates to antibodies specific for cancer markers, compositions and chips containing the same, as well as their uses for cancer detection, managing, monitoring, imaging or treatment, as well as for drug development.
- the invention is particularly suited for detecting, managing or monitoring lung cancer in human subjects. Background
- Lung cancer is the most common cause of death from cancer and each year 1.4 million new cases are diagnosed worldwide. More than two-thirds of lung cancers are diagnosed at a late stage, when clinical symptoms appear. The overall survival rate after diagnosis ranges from 14 % in the USA to 1.1 % in some regions of Asia and is currently very low due to the late diagnosis of the disease.
- Current diagnostics methods are based on imaging techniques and invasive procedures such as bronchoscopy or biopsy 2 .
- the few known plasma biomarkers for lung cancer such as carcinoembryionic antigen (CEA), cytokeratin- 19, squamous cell carcinoma antigen (SCC) and neuron-specific enolase (NSE) lack sufficient sensitivity and specificity 3 to be used as early diagnostics tools. Ongoing efforts using high throughput discovery technologies are still struggling to provide reliable and easily accessible lung cancer biomarkers to enter the clinic ' 5 .
- mAbs provide appropriately validated tools for the characterization and quantitative analysis of proteins but have primarily been targeted at a set of epitopes with low complexity ' .
- Global, antibody proteomics approaches aim to generate libraries of antibodies to cover most or all individual proteins and their immunogenic epitops in any complex proteome.
- Recombinant phage, bacterial and viral display represent approaches to global antibody generation but have had limited success in resulting of libraries capable to detect complex proteomes with sufficient quality affinity reagents and coverage 9 10 .
- the Human Protein Atlas and other large initiatives such as the NCI Clinical Proteomics Technology Initiative 12 are targeted at the generation of comprehensive libraries to the far more complex human proteome with both approaches using recombinant proteins as immunogens.
- the problem with recombinant proteins is that they do not represent the protein natural state, lack post-translational modifications and correct folding, therefore limiting the potential of the obtained libraries to profile natural proteomes.
- An object of the invention relates to particular antibodies, fragments or derivatives thereof, which bind cancer biomarkers, particularly lung cancer biomarkers. These antibodies, either alone or in combination, can be used to detect, manage or monitor cancer in a subject, particularly lung cancer.
- the invention also relates to kits or devices containing such antibodies, suitable for immunologic detection or reaction from any biological sample.
- the invention also relates to nucleic acids, vectors or cells, including hybridomas or recombinant cells, which produce antibodies of the invention.
- the invention is particularly suited to detect or monitor lung cancer in human subjects.
- FIG. 1 The major steps of the monoclonal antibody proteomics process. B
- 181 hybridomas were identified as candidates by showing a ratio higher than 1.5 between the two pools. These candidates were then tested with individual biotinylated depleted plasmas from a second small cohort (collection II) and the obtained candidates were further qualified on two larger cohorts (collection III and IV) of lung cancer samples and controls including non-related cancers and other lung diseases. These qualification steps led to the identification of 13 cloned hybridoma candidates suitable for further development of diagnostics tools.
- FIG. 1 Normalisation of plasma proteins.
- A The number of identified peptides for each protein identified in a shotgun proteomics experiment was plotted against the reported protein concentration in human plasma from the literature for depleted plasma ( ⁇ ) and three different conditions of normalization: (A T *) - loading of 1 mg protein at a flow lml/min
- B Complexity of protein fractions obtained from plasma shown by SDS-PAGE: total plasma (lane 1); depleted plasma using the affinity column Hu7 (lane 2) and Y12 (lane 4); the normalized plasma (lane 3) and glycosylated proteins enriched fraction fromY12 depleted plasma (lane 5).
- FIG. 3 Screening for lung cancer specific antibodies.
- A. Results from HT ELISA of the generated hybridomas with pooled plasma from lung cancer patients (y axis) are plotted against the results obtained with pooled plasma from the matched controls (collection I). Hybridomas considered as primary hits are shown as large circles; colour coding is according to the fusion performed to obtain the hybridomas.
- C. Statistical analysis of the screening results of the validated hits.
- FIG. 4 Receiver operating curves analysis for a single antibody (panel A) and the best panel determined from the data generated with 61 hybridoma supematants (panel B).
- the ROC for the panel was determined either on the testing data set only (50 % of all samples) shown as straight line, or for the entire dataset (including the training seta) shown as dotted line.
- the area under the curve which is a measure for the diagnostics capacity is shown for each curve.
- FIG. 5 High-throughput screening with nascent hybridomas.
- A. The same pool of depleted plasma from healthy donors was biotinylated and a HT-ELISA screening experiment with a panel of 88 mAb hybridoma supematants was performed 6 times on the same day and on 6 different days. The average and standard deviation from the results of the six experiments performed on the same day are plotted on the Y axis versus the average and standard deviations from the six experiments performed over 6 days (X-axis).
- B. The results of the screening experiment performed with two different purifications of the same antibody each spotted in four adjacent wells of the plate with 581 tracers (two tracers per plate) prepared from individual plasma samples.
- Plasma sample was split in two parts and two individual tracers were independently prepared (depletion and biotinylation) and tested with a panel of 88 mAb hybridoma supematants.
- Figure 6. Raw and transformed data from a HT-ELISA screening experiment. All screening data from an experiment performed with plasma collection III and 61 hybridoma supernatants (primary candidates) are plotted as the averaged Vmax (panel A) for each reaction. The results are presented per plate (in this case each plate is reacted with one plasma tracer); the positive controls are shown as red squares and the negative controls as blue squares.
- Panel B The results after normalization using positive and negative controls as described in Methods section "Screening data analysis".
- Figure 7 Algorithm used for building predictive model and determining best panel of biomarker able to discriminate lung cancer and control plasma.
- FIG. 8 Heavy chain V-region sequence of mABs.
- Bsi0033 SEQ ID NO: 77;
- Bsi0068 SEQ ID NO: 77;
- Bsi0076 SEQ ID NO: 82; Bsi0077: SEQ ID NO: 83; Bsi0080: SEQ ID NO: 84;
- Bsi0270 SEQ ID NO: 85; BsiO272: SEQ ID NO: 86; BsiO349: SEQ ID NO: 87; BsiO351 : SEQ ID NO: 88; BsiO352: SEQ ID NO: 89; BsiO358: SEQ ID NO: 90; BsiO359: SEQ ID NO: 85; BsiO272: SEQ ID NO: 86; BsiO349: SEQ ID NO: 87; BsiO351 : SEQ ID NO: 88; BsiO352: SEQ ID NO: 89; BsiO358: SEQ ID NO: 90; BsiO359: SEQ ID NO: 85; BsiO272: SEQ ID NO: 86; BsiO349: SEQ ID NO: 87; BsiO351 : SEQ ID NO: 88; BsiO352: SEQ ID NO: 89; Bsi
- FIG. 9 BSI0392 mAB. Relative individual (•) and descriptive statistics (box plots) of levels of cognate antigen recognized by mAB BSI0392 in the plasma of control subjects and LC patients (A). SDS PAGE (reduced) followed by Western blotting (B).
- FIG. 10 BSI0352 mAB. Relative individual (•) and descriptive statistics (box plots) of levels of cognate antigen recognized by mAB BSI0352 in the plasma of control subjects and LC patients.
- BSI0351 mAB Relative individual (•) and descriptive statistics (box plots) of levels of cognate antigen recognized by mAB BSI0351 in the plasma of control subjects and LC patients.
- BSI0358 mAB Relative individual (•) and descriptive statistics (box plots) of levels of cognate antigen recognized by mAB BSI0358 in the plasma of control subjects and LC patients .
- SDS PAGE reduced
- Western blotting of normal control and lung cancer plasma samples B. Immunohistological staining of paraffin embedded formaldehyde fixed tissue samples after antigen retrieval. Inserts are from HE stained tissue (2Ox primary objectives). Adenocarcinoma (upper) and squamous cell carcinoma (lower) panel. (C).
- BSI0359 mAB Relative individual (•) and descriptive statistics (box plots) of levels of cognate antigen recognized by mAB BSI0359 in the plasma of control subjects and LC patients (A).
- B Figure 14.
- BSI0271 mAB Relative individual (•) and descriptive statistics (box plots) of levels of cognate antigen recognized by mAB BSI0271 in the plasma of control subjects and LC patients (A).
- FIG. 15 BSI0033 mAB. Relative individual (•) and descriptive statistics (box plots) of levels of cognate antigen recognized by mAB BSI0033 in the plasma of control subjects and LC patients (A). SDS PAGE (reduced) followed by Western blotting of a non reduced plasma sample. Note the haptoglobin specific ladder, which is due to polymerization of haptoglobin in the plasma (B).
- Figure 16 BSI0071 mAB. Relative individual (•) and descriptive statistics (box plots) of levels of cognate antigen recognized by mAB BSI0071 in the plasma of control subjects and LC patients (A).
- Figure 17. Histogram distribution of accuracy (AUC from ROC curves). Data from 408 patients (189 Ctrl & 219 LC) and 10 mAbs used in the analysis. LDA function with Leave- one-out cross validation. All possible combinations (1013) of the 10 mABs were tested.
- FIG. 19 ROC curve and formula classifiers for the panel of BSI0272, BSI0358 and BSI0392 mABs.
- Accuracy (AUC) is 0.89. Two thresholds; (i) with 0.876 sensitivity and 0.71 specificity and (ii) with 0.78 sensitivity and 0.88 specificity are marked.
- a challenge in the treatment of lung cancer is the lack of early, pre-symptomatic detection as lung cancer symptoms generally present at advanced stages.
- Further tests with plasma from patients with other inflammatory lung diseases and non-related cancers confirmed the lung cancer specificity of the monoclonal antibodies.
- the cognate antigen was identified for these antibodies, as well as binding peptides thereof.
- Fig. IA mAB proteomics
- Fig. IB complex antigen
- Hybridomas were obtained by PEG mediated fusion of spleen cells from the immunized mice with the Sp2/0-Ag-14 mouse myeloma cell line . Fused cells were seeded in microwells and their IgG production was estimated as the IgG concentration measured in the cell supernatants. IgG containing wells with at least 50 ng/ml IgG (27% of all fused cells) were then tested with biotinylated plasma tracers using direct ELISA in a series of screening experiments (Fig. IB) designed to identify antibodies capable of detecting lung cancer specific biomarkers.
- the screening experiments were based on direct ELISA using kinetic reading and the reproducibility of our assay (see Figure 5) allowed us to measure differences in the concentration of the antibody-antigen complex as low as 1.5. In the range of antigen concentrations below the saturation of the available antibody, the observed differences in the majority of the cases would be directly reflecting a difference in the biomarker concentration.
- the first three steps of the screening strategy aimed at identifying the antibodies with a good potential to discriminate cancer patients from control subjects. In the initial step, all IgG producing hybridomas from the two generated libraries were screened with pooled depleted and biotinylated plasma from twenty, apparently healthy control subjects and from twenty non-small cell lung-cancer patients (collection I) (Fig 3a).
- the plasma pooling was necessary to reduce the need for biological material (hybridoma supernatants and quantity of plasma) and to reduce the biological variability at this step 7 .
- the 184 nascent hybridoma supernatants selected to detect a differential ratio between the two pools higher than 1.5 were in their majority (87%) cancer specific.
- the next steps of screening were aimed at better qualifying the capacity of the selected antibodies to distinguish plasma from lung cancer patients from control subjects. This required screening experiments using tracers obtained from the individual plasmas.
- the plasma processing (depletion of highly abundant proteins and labelling with biotin) is highly reproducible (Figure 5C) and allowed us to compare signals obtained with the antibody candidates on hundreds of plasmas.
- Redundancy of the group of specific antibodies was assessed by V-region sequencing of the IgG, and the results confirmed independent clones for all of our candidates.
- the analysis of the functional redundancy showed several pairs of antibodies (e.g., BSI0070/BSI0072 and BSI0351/BSI0352) with similar reactivity and the results was confirmed by competitive ELISA experiments between these pairs that indicated the recognition of distinct epitopes on the same antigen by antibodies from each pair (data not shown).
- the cognate antigens for these 10 mAB have been identified, as well as binding peptide sequences thereof.
- Three mABs are specific for LRGl (Leucine rich glycoprotein 1), two mABs recognize Haptoglobin and Haptoglobin related protein (HRP), one mAB recognizes C9 (complement factor 9), two mABs recognize CHF (complement factor H), and two bind Alpha- 1-antichymo trypsin (ACT, Serpin A3).
- mABs also react with cancer cells in-situ, as detected by immunohistology, allowing their use for histopathological classification, immunological or immunohisto logical staining, and/or imaging of cancer.
- the invention thus provides novel antibodies which represent highly valuable reagents for cancer detection, management, diagnosis, monitoring, histopathological classification, staining, or imaging.
- the invention therefore relates to an antibody which binds a peptide having a sequence selected from SEQ ID NOs: 1 to 76 (see Table 4 below), or a fragment or derivative of such an antibody having the same antigen specificity.
- Binding peptides recognized by antibodies of the invention are disclosed below. These peptides have been tested in phage display ELISA. Bold peptide sequences also bind to the corresponding mABs in biotinylated form, immobilized to avidin coated 96 well plates, in direct ELISA experiments. Binding competition, displacement with human plasma and specific purified antigen was also confirmed for some peptides.
- the invention relates to an antibody which binds a polypeptide comprising a peptide sequence selected from SEQ ID NOs: 1 to 76, or a fragment or derivative of such an antibody having the same antigen specificity.
- the invention relates to an antibody which binds a peptide selected from SEQ ID NO: 26-35 and 57-63 and which also binds a human LRGl (Leucine Rich Alpha -2 Glycoprotein 1) protein, or a fragment or derivative of such an antibody having the same antigen specificity.
- the invention particularly relates to an antibody which binds a peptide selected from SEQ ID NO: 26-35 and 57-63 and wherein said binding is at least partially displaced by a human LRGl protein, or a fragment or derivative of such an antibody having the same antigen specificity.
- Lung cancer specific antibodies binding to other peptide sequences have also been isolated.
- Corresponding antibodies and peptides are listed in table 6 (SEQ ID NO: 93-135).
- the invention also relates to an antibody which binds a peptide having a sequence selected from SEQ ID NOs: 93-135 (see Table 6), or a fragment or derivative of such an antibody having the same antigen specificity.
- Another particular preferred embodiment of the invention relates to an antibody which binds a peptide selected from SEQ ID NOs: 14-25 and which also binds a human C9
- (Complement component 9) protein or a fragment or derivative of such an antibody having the same antigen specificity.
- the invention particularly relates to an antibody which binds a peptide selected from SEQ ID NOs: 14-25 and wherein said binding is at least partially displaced by a human C9 protein, or a fragment or derivative of such an antibody having the same antigen specificity.
- a particularly preferred antibody of the invention binds a peptide selected from SEQ ID NOs: 14-22 and 24 and binds a human C9 protein, or a fragment or derivative of such an antibody having the same antigen specificity.
- Another particular preferred embodiment of the invention relates to an antibody which binds a peptide selected from SEQ ID NOs: 36-38 and which also binds a human haptoglobin or haptoglobin-related protein, or a fragment or derivative of such an antibody having the same antigen specificity.
- the invention particularly relates to an antibody which binds a peptide selected from SEQ ID NOs: 36-38 and wherein said binding is at least partially displaced by a human haptoglobin or haptoglobin-related protein, or a fragment or derivative of such an antibody having the same antigen specificity.
- Another particular preferred embodiment of the invention relates to an antibody which binds a peptide selected from SEQ ID NOs: 43-56 and 64-76 and which also binds a human CFH (Complement factor H, formerly known as Beta IH globulin) protein, or a fragment or derivative of such an antibody having the same antigen specificity.
- the invention particularly relates to an antibody which binds a peptide selected from SEQ ID NOs: 43-56 and 64-76 and wherein said binding is at least partially displaced by a human CFH protein, or a fragment or derivative of such an antibody having the same antigen specificity.
- a particularly preferred antibody of the invention binds a peptide selected from SEQ ID NOs: 64-71, 73 and 75-76 and also binds a human CFH protein, or a fragment or derivative of such an antibody having the same antigen specificity.
- Another particular preferred embodiment of the invention relates to an antibody which binds a peptide selected from SEQ ID NOs: 1-13 and 39-42 and which also binds a human Alpha- 1-antichymo trypsin protein, or a fragment or derivative of such an antibody having the same antigen specificity.
- the invention particularly relates to an antibody which binds a peptide selected from SEQ ID NOs: 1-13 and 39-42 and wherein said binding is at least partially displaced by a human Alpha- 1-antichymo trypsin protein, or a fragment or derivative of such an antibody having the same antigen specificity.
- a particularly preferred antibody of the invention binds a peptide selected from SEQ ID NOs: 1-5 and 7-12 and also binds a human Alpha- 1 -antichymo trypsin protein, or a fragment or derivative of such an antibody having the same antigen specificity.
- antibodies of this invention comprise all or part of a heavy chain variable region sequence selected from SEQ ID NOs: 77-92 ( Figure 8).
- the polypeptide may be or may comprise a complete variable region of an antibody, or may comprise only a part thereof, such part preferably comprising at least 5 consecutive amino acid residues, more preferably at least 6, 7 or 10 consecutive amino acid residues.
- a preferred polypeptide of the invention is a polypeptide comprising at least a CDR or FR domain of any one of SEQ ID NOs: 77-92.
- the FR domains are represented in blue (or grey) on Figure 8, while the CDR domains are represented in white.
- Variant sequences wherein from 1 to 10 amino acid residues have been replaced, deleted or inserted are also included in the present invention, as long as the modification does not substantially alter antigen binding capacity or specificity of the sequence or domain.
- antibodies of the invention typically contain 1, 2 or 3 amino acid modifications, typically consisting of replacement with amino acid of same nature.
- Illustrative and preferred examples of antibodies of the invention include monoclonal antibodies BsiO358, BsiO359, BsiO272, BsiO392, Bsi0080, BsiO352, Bsi0077, BsiO349, Bsi0270, BsiO271, Bsi0072, Bsi0076, Bsi0068, Bsi0033, Bsi0071, Bsi351, or Bsi0070, or a fragment or derivative thereof having the same antigen specificity.
- These antibodies comprise a variable region sequence as disclosed in SEQ ID NOs: 77-92, respectively.
- a further object of the invention is a peptide consisting of an amino acid sequence selected from SEQ ID NOs: 1 to 76.
- a further object of the invention is an isolated nucleic acid encoding an antibody of the invention, or the fragment or derivative of said antibody.
- the nucleic acid typically encodes at least a portion of a variable region of the antibody, e.g., a portion of the heavy or light chain including a variable domain, such as a CDR or FR domain.
- the nucleic acid may be DNA or RNA, including cDNA, gDNA, recombinant DNA, synthetic or semi-synthetic DNA, which may be single- or double-stranded.
- a particular object of the invention is a nucleic acid encoding a polypeptide comprising at least a CDR or FR domain of any one of SEQ ID NOs: 77-92.
- the nucleic acid may be fused to other regions (e.g., constant regions, hinge regions, etc) to create synthetic antibodies, humanized antibodies, chimeric antibodies, etc., according to techniques well known per se in the art. They may also be used to produce single chain antibodies.
- the invention relates to antibodies (or fragments or derivatives thereof) which "bind" peptides or polypeptides.
- binding should be specific or selective, meaning that the binding to the reference peptide or polypeptide can be discriminated from (e.g., occurs with higher affinity or avidity than) possible non specific binding to other antigens.
- Preferred antibodies do not bind, under selective condition, to any other unrelated human blood protein but the reference protein. Binding of an antibody to the above reference peptide can be tested as disclosed in the examples. Binding to a peptide can be verified with either the isolated peptide (e.g., immobilized on a support) or with the peptide included in a larger polypeptide sequence.
- the peptide is in isolated form and immobilized on a support (e.g., a plate) and the candidate antibody is incubated with the immobilized peptide. Binding may then be revealed using known techniques. Binding to a protein may be tested by incubating any sample containing the protein in solution, and verifying the formation of an immune complex.
- the term "binding" to a peptide indicates the antibody can bind the corresponding peptide in biotinylated form, immobilized to avidin coated well plates in direct ELISA experiments.
- the antibody may be a polyclonal or a monoclonal antibody, most preferably a monoclonal. It may be of various classes (e.g., IgG, IgE, IgM, etc.). The antibody may be of various animal origin, or human or synthetic or recombinant. Furthermore, the term antibody also includes fragments and derivatives thereof, in particular fragments and derivatives of said monoclonal or polyclonal antibodies having substantially the same antigenic specificity. Antibody fragments include e.g., Fab, Fab '2, CDRs, etc). Derivatives include humanized antibodies, human antibodies, chimeric antibodies, poly- functional antibodies, Single Chain antibodies (ScFv), etc.
- ScFv Single Chain antibodies
- polyclonal antibodies may be produced according to conventional methods, including immunization of an animal and collection of serum (polyclonal) or spleen cells (to produce hybridomas by fusion with appropriate cell lines).
- Methods of producing polyclonal antibodies from various species, including mice, rodents, primates, horses, pigs, rabbits, poultry, etc. may be found, for instance, in Vaitukaitis et al.
- the antigen is combined with an adjuvant (e.g., Freud's adjuvant) and administered to an animal, typically by sub-cutaneous injection. Repeated injections may be performed. Blood samples are collected and immunoglobulins or serum are separared.
- an adjuvant e.g., Freud's adjuvant
- Recombinant antibodies of the invention may be produced by methods known per se in the art, for example by recombination in a host cell, transformed with one or more vectors enabling the expression and/or secretion of the nucleotide sequences encoding the heavy chain or the light chain of the antibody.
- the vector generally contains a promoter, translation initiation and termination signals, and suitable transcriptional regulatory regions. It is stably maintained in the host cell and may optionally possess specific signals for secretion of the translated protein. These different components are selected and optimized by one of skill in the art according to the host cell used.
- Another object of the invention is an expression vector, for example a viral or plasmid vector, comprising a nucleic acid of the invention.
- the vector may replicate autonomously in the chosen host cell, or it may be an integrative vector.
- an expression vector comprising a nucleic acid coding for the light chain of the antibody.
- Another object of the invention is an expression vector comprising a nucleic acid coding for the heavy chain of an antibody of the invention.
- Such vectors are prepared by methods known per se in the art, and the resulting clones may be introduced into a suitable host cell by standard methods, such as lipofection, electroporation, use of polycationic agents, heat shock, or chemical methods.
- the host cell may be selected from among prokaryotic or eukaryotic systems, for example bacterial cells but also yeast cells or animal cells, in particular mammalian cells. Insect cells or plant cells may also be used.
- Another object of the invention is a hybridoma cell producing an antibody of the invention.
- the invention in another aspect, relates to a method for producing an antibody of the invention, said method comprising the following steps : a) culturing in a suitable culture medium a host cell expressing a heavy chain and/or a light chain such as defined herein; and b) recovering said antibodies so produced from the culture medium or from said cultured cells.
- a suitable culture medium a host cell expressing a heavy chain and/or a light chain such as defined herein
- recovering said antibodies so produced from the culture medium or from said cultured cells a method for producing an antibody of the invention, said method comprising the following steps : a) culturing in a suitable culture medium a host cell expressing a heavy chain and/or a light chain such as defined herein; and b) recovering said antibodies so produced from the culture medium or from said cultured cells.
- H chain heavy chain
- L chain light chain
- a double-recombinant vector may be prepared in which the sequence encoding each of the H and L chains is under the control of a
- a particular example of a production method is production in an insect cell, as described for example in international patent application WO 96/07740.
- an expression cassette is used comprising a sequence coding for the variable region of the monoclonal antibody light chain, or a sequence coding for the variable region of the monoclonal antibody heavy chain, said sequence is placed under transcriptional control of a suitable promoter, for example a baculovirus promoter.
- a production method is the use of a viral or plasmid expression vector for expressing the monoclonal antibody in a mammalian cell.
- Preferred mammalian cells for expressing the monoclonal antibody are the rat YB2/0 line, the hamster CHO line, in particular the lines CHO dhfr- and CHO Led 3, PER.C6TM (Crucell), 293, K562, NSO, SP2/0, BHK or COS, C0S7.
- a further production method is the expression of the recombinant antibody in transgenic organisms, for example in plants (Ayala M, Gavilondo J, Rodriguez M, Fuentes A, Enriquez G, Perez L, Cremata J, Pujol M. Production of plantibodies in Nicotiana plants. Methods MoI. Biol. 2009; 483: 103-34) or else in the milk of transgenic animals such as rabbit, goat or pig (Pollock, D.P., J.P. Kutzko, E. Birck- Wilson, J.L. Williams, Y. Echelard and H. M. Meade. (1999) Transgenic milk as a method for the production of recombinant antibodies. Journal of Immunological Methods. 231: 147-157).
- the antibodies of the invention may be coupled to heterologous moieties, such as toxins, labels, drugs or other therapeutic agents, covalently or not, either directly or through the use of coupling agents or linkers.
- Labels include radiolabels, enzymes, fluorescent labels, magnetic particles and the like.
- Toxins include diphteria toxins, botulinum toxin, etc.
- Drugs or therapeutic agents include lymphokines, antibiotics, antisense RNA or antisense nucleic acid, modified or not, growth factors, etc. Methods of using such heterologous moieties are illustrated, for instance, in US4,277,149 and US3,996,345.
- the antibodies of this invention have various applications, including, diagnostic, purification, detection, therapeutic, prophylactic, etc.
- these antibodies In vitro, they can be used as screening agents or to purify the antigen from various samples, including various biological samples (e.g., blood samples). As demonstrated in the examples, these antibodies have the remarkable property of binding to antigens which are differentially expressed between cancerous and control human subjects.
- the invention thus relates to a diagnostic composition
- a diagnostic composition comprising an antibody (or a fragment or derivative thereof) as defined above.
- the composition may comprise any excipient or solid support.
- the invention also relates to a method for detecting lung cancer in a subject, the method comprising contacting a sample from said subject, preferably a blood sample, with at least one antibody as defined above and determining the presence of an antigen bound to said at least one antibody, said presence being indicative of lung cancer.
- the method preferably comprises contacting said sample from said subject with at least two antibodies as defined above, preferably at least 3, in combination.
- the invention discloses particular antibody combinations which allow specific and sensitive determination of lung cancer in human subjects. These combinations include, without limitation:
- a preferred type of combinations comprises BsiO392 in combination with at least one or two additional antibodies.
- Another preferred type of combinations comprises Bsi0071 in combination with at least one or two additional antibodies.
- Another preferred type of combinations comprises BsiO272 in combination with at least one or two additional antibodies.
- Another preferred type of combinations comprises BsiO358 in combination with at least one or two additional antibodies.
- Another preferred type of combinations comprises Bsi0077 in combination with at least one or two additional antibodies.
- Another preferred type of combinations comprises at least one anti-C9 antibody in combination with at least one or two additional antibodies.
- the term "combination” indicates the sample should be tested for antigen binding to all antibodies of the combination, either simultaneously or separately (e.g., sequentially). Preferably, the antibodies are tested simultaneously (e.g., on the same device).
- a further object of this invention resides in a device comprising at least one antibody as defined above immobilized on a support.
- the support may be, e.g., a membrane, a slide, a microarray, a chip or a microbead. Immobilization can be made through techniques known per se in the art (using linkers, cross linking reagents, passive adsorption, etc.).
- a further object of the invention resides in a method for detecting lung cancer in a subject, the method comprising contacting a sample from said subject, preferably a blood sample, with at least one antibody that binds a Leucine-Rich alpha-2 glycoprotein (LRGl) and determining the presence of an antigen bound to said at least one antibody, said presence being indicative of lung cancer.
- a sample from said subject preferably a blood sample
- at least one antibody that binds a Leucine-Rich alpha-2 glycoprotein (LRGl) determining the presence of an antigen bound to said at least one antibody, said presence being indicative of lung cancer.
- a further object of the invention is a method for detecting lung cancer in a subject, the method comprising contacting a sample from said subject, preferably a blood sample, with at least one antibody that binds a haptoglobin (HP) or HRP protein, and determining the presence of an antigen bound to said at least one antibody, said presence being indicative of lung cancer.
- a sample from said subject preferably a blood sample
- a further object of the invention is a method for detecting lung cancer in a subject, the method comprising contacting a sample from said subject, preferably a blood sample, with at least one antibody that binds a C9 protein and determining the presence of an antigen bound to said at least one antibody, said presence being indicative of lung cancer.
- a further object of the invention is a method for detecting lung cancer in a subject, the method comprising contacting a sample from said subject, preferably a blood sample, with at least one antibody that binds a CFH protein and determining the presence of an antigen bound to said at least one antibody, said presence being indicative of lung cancer.
- a further object of the invention is a method for detecting lung cancer in a subject, the method comprising contacting a sample from said subject, preferably a blood sample, with at least one antibody that binds an Alpha- 1 -anti chymotrypsin (ACT, SERPINA3) protein and determining the presence of an antigen bound to said at least one antibody, said presence being indicative of lung cancer.
- Preferred methods comprise contacting said sample from said subject with at least two antibodies which bind a distinct protein selected from Leucine -Rich alpha-2 glycoprotein, haptoglobin, haptoglobin related protein, C9, CFH or Alpha- 1-antichymo trypsin.
- Further preferred methods comprise contacting said sample from said subject with at least three distinct antibodies which bind a distinct protein selected from Leucine-Rich alpha-2 glycoprotein, haptoglobin, C9, CFH or Alpha 1 Antichymotrypsin.
- antibody as used therein also includes fragments and derivatives thereof as defined above.
- a further object of the invention is a device comprising at least one antibody that binds a protein selected from Leucine-Rich alpha-2 glycoprotein, haptoglobin, haptoglobin related protein, C9, CFH or Alpha- 1 -antichymotrypsin, immobilized on a support.
- a further object of the invention is a device comprising at least two antibodies that each bind a distinct protein selected from Leucine-Rich alpha-2 glycoprotein, haptoglobin, C9, CFH or Alpha-1-antichymotrypsin, immobilized on a support.
- the support may be a membrane, a slide, a microarray, a chip or a microbead based detection system.
- a further object of the invention is a kit comprising a device as defined above and a reagent to perform or detect (or quantify) an immune reaction, particularly an antibody-antigen complex.
- Reagents include labels, buffers, substrates, etc.
- the kits typically comprise containers for the different reagents and products, and may further comprise a support or other device suitable to perform the assay.
- the antibodies can be used individually or in combination to measure the level of the cognate antigen (analyte) in biofiuids including serum, plasma, urine, cerebrospinal fluid, bronchoalveolar lavage (BAL) fluid, sputum, tear, sweat, amniotic fluid and inflammatory exudate, using any number of detection technologies or platforms such as, without limitation Capture assay, Sandwich assay, Competition assay, Radio-immuno assays, Enzyme labels with substrates that generate colored, fluorescent, chemiluminescent, or electrochemically-active products, Fluorescence, fluorescent polarization, Chemiluminescence, Optical and colorimetric, Electrochemiluminescence, Time -resolved fluorescence, Surface plasmon resonance, Evanescent wave, Multiwell plate (ELISA), Individual assay, Multiplex assay, Latex bead - multiplex assay, Microarray (Laminar surface) - multiplex assay, Glass, Ceramic (like Randox), Plate based
- the antibody is immobilized directly to the support or captured by an affinity reagent such as an anti-mouse IgG antibody coated onto the support.
- the immobilized antibody is then incubated with any of the above mentioned body fluids in which the proteins have been labeled with a detection molecule such as biotin, with or without pre -treatment to remove abundant proteins.
- a detection molecule such as biotin
- the labeled protein which is bound by the antibody is detected by the addition of an appropriate detection reagent which binds to the label such as avidin or streptavidin which has been modified to be compatible with one of the detection technologies described in the section "detection technology.”
- the first antibody is immobilized directly to the support or captured by an affinity reagent such as an anti-mouse IgG antibody coated onto the support.
- the immobilized antibody is then incubated with any of the above mentioned body fluids, with or without pre-treatment to remove abundant proteins.
- the antibody/antigen complex is then incubated with a second antibody, made against the same protein, which has been labeled with a detection molecule such as biotin.
- the bound antibody is detected by the addition of an appropriate detection reagent which binds to the label such as avidin or streptavidin which has been modified to be compatible with one of the detection technologies described in the section "detection technology.”
- the resulting signal provides a quantitative measure of the amount of protein bound by the antibody
- the antibody is immobilized directly to the support or captured by an affinity reagent such as an anti-mouse IgG antibody coated onto the support.
- the immobilized antibody is then incubated with any of the above mentioned body fluids.
- the immobilized antibody/antigen complex is then incubated with a labeled tracer consisting of either (1) any of the above mentioned body fluids in which the proteins have been labeled with a detection molecule such as biotin, with or without pre -treatment to remove abundant proteins, or (2) a purified or recombinant protein recognized (bound) by the monoclonal antibody, or (3) a peptide which is recognized (bound) by the monoclonal antibody.
- the labeled protein or peptide which is bound by the antibody is detected by the addition of an appropriate detection reagent which binds to the label such as avidin or streptavidin which has been modified to be compatible with one of the detection technologies described in the section "detection technology.”
- Preferred Detection Technologies include:
- Enzyme labels with substrates that generate colored, fluorescent, chemiluminescent, or electrochemically-active products are enzyme labels with substrates that generate colored, fluorescent, chemiluminescent, or electrochemically-active products .
- the detection reagent (for example steptavidin or avidin, which binds to biotin) is coupled to an enzyme such as horseradish peroxidase which is capable of catalyzing o an appropriate colorimetric substrate of which the product demonstrates maximal absorbance at a given wavelength allowing the quantitative measurement of the labeled protein by measuring the optical density of the final product in the well at or near the wavelength of maximal absorbance.
- an enzyme such as horseradish peroxidase which is capable of catalyzing o an appropriate colorimetric substrate of which the product demonstrates maximal absorbance at a given wavelength allowing the quantitative measurement of the labeled protein by measuring the optical density of the final product in the well at or near the wavelength of maximal absorbance.
- o a chemiluminescent substrate to a sensitized reagent which upon oxidation emits light, providing the quantitative measurement of the labeled protein.
- a chemiluminescent substrate to a sensitized reagent which upon the application of an electrical current emits light,
- the detection reagent for example steptavidin or avidin, which binds to biotin
- the detection reagent is coupled to a fluorescent tag.
- Preferred platform Technologies include:
- o Single test one antibody is immobilized per well either directly or indirectly using a capture reagent such as goat anti-mouse antibody.
- o Multiplex 2 or more antibodies are immobilized in a single well by deposition in a pattern
- Two or more antibodies are immobilized onto a latex bead between x and y microns
- Two or more antibodies are spotted onto an activated laminar surface with a spot diameter between 100 ⁇ m - 5 mm (arrays), 2 ⁇ m - 100 ⁇ m (microarrays), 10 nm-2 ⁇ m (nano-arrays)
- the surface can be composed of glass, plastic, ceramic, carbon nanotube lattice etc.
- the method can be performed at any stage of the disease, such as early or late stage, to confirm or reject a prior diagnosis, select patients for surgery, classify cancer type or severity, or monitor patients. The test may also be conducted before disease symptoms, as a first line detection.
- the test will avoid futile thoracotomies and unnecessary and expensive imaging technologies that are not specific enough and expose the patients to potentially harmful irradiation, and missed cures as observed patients could receive the test repeatedly.
- Plasma specimens were in part purchased from Proteogenex (Culver, CA) and Asterand (Royston, UK). Other samples (see Table 1) were collected at the Department of Pulmonology of the University of Debrecen in Hungary from informed and consented patients and matched (age, sex and smoking habit) apparently healthy individuals by a clinical protocol RKEB/IKEB:2422-2005 approved by the regional ethics committee and the IRB of the clinic.
- a plasma sample (250 uL) was thawed and diluted by addition of 750 uL of buffer A (25 mM Tris, 0. 5M NaCl, ImM MnC12, ImM CaC12 and 0.05% sodium azide, pH 7.4).
- buffer A 25 mM Tris, 0. 5M NaCl, ImM MnC12, ImM CaC12 and 0.05% sodium azide, pH 7.4
- the diluted plasma was loaded onto the Seppro 12 column at a flow rate of 0.5mL/min for 30 min.; the flow rate was then increased to 2 mL/min for the remainder of the run.
- the unbound proteins (depleted fraction) were washed off with binding buffer and the depleted fraction was collected into a 15 mL centrifugal filter Amicon with a cut-off at 5kDa.
- the depleted plasma was concentrated by centrifugation at 3,500 x g.
- the bound proteins were eluted from the column with stripping buffer (100 mM glycine, pH 2.5) and collected into a separate tube.
- the column packing material was neutralized with 100 mM Tris-HCl, pH 8.0 for 10 min and re-equilibrated with binding buffer, before performing protein depletion from the next plasma sample.
- a total of 27 depletion runs for the normal plasma and 20 runs for the lung cancer plasma were performed.
- the concentrated and depleted fractions from each group were pooled before further processing. - depletion of high abundant proteins from individual plasma samples for tracers preparation
- the depletion of the seven most abundant proteins was performed using commercially available Human-7 Multiple Affinity Removal System columns (10X100mm) from Agilent Technologies (Santa Clara, CA). The process was automated using a chromatography system AKTATMpurifier 10 - collector F950" from GE Healthcare (Chalfont St. Giles, UK) connected to an autosampler A-900. The individual plasmas (70 uL) were diluted four times with the vendor provided equilibration buffer (buffer A) and filtered using 0.22 ⁇ m spin filters at 16000 g for 1 min. The filtered plasmas were loaded on the column at a flow rate of 0.
- MARS Hu-7 columns were used according to the vendor specifications for maximum of 200 runs and their performance was followed at regular intervals (each 40 runs) for protein leaking (albumin, IgG, IgA and fibrinogen) by an ELISA using commercially available mAbs.
- Glycoprotein enrichment was performed using a multi-lectin affinity chromatography (M- LAC) column.
- M- LAC multi-lectin affinity chromatography
- the lectin column contains a mixture of 3 lectins: Con A, WGA and JAC from Vectors Laboratories (Burlingame, CA) and was prepared in-house using Aldehyde POROS- 20 AL® (20 ⁇ m beads) beads from Applied Biosystems, (Foster City, CA) as previously reported 15 .
- One mL of the pooled depleted plasma sample was loaded on a 7.8 mL M-LAC column (10 x 100) at a flow rate of 0.5 mL/min for 20 min.
- the flow rate was increased to 4 mL/min, and the unbound proteins (flow through fraction) were washed-off with M-LAC binding buffer (25 mM Tris, 0. 5OM NaCl, ImM MnCl 2 , ImM CaCl 2 and 0.05% sodium azide, pH 7.4) for 10 min.
- M-LAC binding buffer 25 mM Tris, 0. 5OM NaCl, ImM MnCl 2 , ImM CaCl 2 and 0.05% sodium azide, pH 7.4
- the flow through fraction was collected and stored at -75°C.
- the proteins which bound to the M-LAC were eluted with 100 mM acetic acid, pH 3.8 at 4 mL/min for 10 min.
- the eluted glycoproteins were collected directly into a 15 mL Amicon filter device and concentrated as described above.
- the sample was buffer exchanged into IX PBS by addition of 14 mL of buffer to the filter device; the volume was reduced down to ⁇ 1.0 mL by centrifugation; this step was repeated twice.
- the M-LAC column was neutralized with 0.5 M Tris, pH 7.5, IM NaCl, 0.05 % sodium azide and equilibrated prior to the next run.
- the bound glycoproteins from 5 runs were pooled, aliquoted and stored at -75°C. The total glycoprotein yield was approximately 5.0 mg for the lung cancer and 3.0 mg for the matched control samples.
- Protein normalization of the depleted plasma and the glycosylated protein fraction was performed using an in-house immunoaffinity column prepared as follows: rabbit polyclonal antibodies raised against normal human serum from Sigma (Saint Louis, MO) were covalently linked to HiTrap Protein G HP column (4.6 x 100) from GE Healthcare (Chalfont St. Giles, UK) using 15 mM dimethyl pimelimidate and 15 mM dimethyl suberimidate as previously described .
- HiTrap Protein G HP column 4.6 x 100
- GE Healthcare Chalfont St. Giles, UK
- Ix PBS buffer pH 7.0
- the flow through represented the normalized protein fraction, while the bound proteins were eluted with stripping buffer B from Agilent Technologies (Santa Clara, CA).
- the column was equilibrated with Ix PBS.
- the pooled or individual depleted plasma was labeled with a bifunctional NHS-biotin having a long alkyl chain as a spacer EZ-Link Sulfo-NHS-LC-Biotin from Pierce (Rockford, IL). Labeling was performed in PBS buffer (pH 7.0) at a 100 time molar excess of biotin assuming an average protein mass of 68 kDa for 30 min. at room temperature. The non-reacted protein was removed using a 5 ml HiTrap desalting column HP from GE Healthcare (Chalfont St. Giles, UK) with PBS (pH 7.0) at a flow rate of 1 ml/min. Immunisation of BALB/c mice
- mice Two groups of four female Balb/c mice of at least 8 weeks of age from Charles River Laboratories (Evry, France) were injected subcutaneously in the rear footpads and at the base of the tail with the two complex antigen protein mixtures. Each mice received 10 ⁇ g protein of glycoprotein enriched depleted plasma (group A) and normalized glycoprotein enriched depleted plasma (group B) on days 1, 15 and 29. Complete Freund's adjuvant (Sigma, Saint Louis, MO) was used in all cases. Blood was taken from each mouse by retro- orbital bleed using a Pasteur pipette on days 19 and 33 to monitor antibody production by ELISA.
- reaction development was carried out by adding 20 ⁇ l freshly prepared substrate solution to each well (o-phenylenediamine at 0.4 mg/ml in 0.05 M phosphate/citrate buffer pH 5.0). The kinetics of the reaction development at 37 0 C was followed at 450 nm by recording the absorbance multiple times.
- Liquid handling was performed using Multidrop Combi from Thermo (Waltham, MA), Multimek with 96 pin head from Beckman Coulter (Fullerton, CA) and STAR from Hamilton (Reno, NV). Plate washing was performed using ELX405 from BioTek (Winooski, VT). Absorbance was measured with a microplate reader SpectraMax from Molecular Device (MDS, Toronto, Canada).
- Vmax of the chromogenic reactions were calculated from the linear part of the kinetic readings using the software provided with the plate reader SoftMax Pro from Molecular Device (MDS, Toronto, Canada). Each plate had eight positive and negative controls used to calculate Z' factor, a metrics used to quantify the quality of the screening experiment with respect to reproducibility and data scatter . Plates with a Z' factor below 0.5 (usually less than 10% in a screening campaign) were repeated. The positive (PC) and negative controls (NC) were used to normalize the data across plates and according to the following formula:
- VmaxN sam pie (Vmax samp i e -Vmax NC )/ (Vmax PC -Vmax NC ).
- Aberrant data (outliers) for each group of replicates were removed using automated procedure based on the mean and standard deviation values of the multiple measurements.
- CF is a normalized measure of dispersion of the probability distribution and it is defined as the ratio of the standard deviation ⁇ to the mean ⁇ as follows:
- T max (i) ⁇ (i) + 1.3* ⁇ (i)
- the dataset was partitioned randomly into two parts (Figure 7), a training dataset and a testing dataset with a respective size of 50%(75%) and 50%(25%) of the available cancer and control samples from collection III.
- the classifiers were built and tested on the training set and the best one was finally applied on the testing data set to determine the diagnostic accuracy of the classifier.
- Selection of hybridomas for building the classifier was carried out by ranking the hybridomas according the p-values obtained for each one of them in comparing the results between the two groups (control vs lung cancer) using the Mann- Whitney test.
- LDA Linear Discriminant Analysis
- AUC area under the receiver operating curve
- the R statistical software (available from www.cran.r-project.org) was used for the statistical analysis and for the implementation of the algorithm.
- the Ph.D-12TM Phage Display Peptide Library Kit was obtained from New England Biolabs (Beverly, MA). The phages display random peptide 12-mers are fused to a minor coat protein (pill) of M13 phage. The library consists of approximately 2.7x10 sequences. The experiments were carried out as described in the Instruction Manual of the Phage Display Kit with minor modifications. Phages were propagated using the supplied E. coli (ER2738) host strain. 96-well microtiter plates (Maxisorp Cat. no. 442404, Nunc, Napperville, IL) were coated with the mapped mAbs (10 ⁇ g antibody in 100 ⁇ l 0.1 M NaHCO 3 pH-8.6/well).
- 4xlO 10 phages were added in TBS-Tween to the wells and incubated for 1 hour at room temperature. Bound phages were eluted by lowering the pH (0.2 M Glycine -HCl pH 2.2). Recovered phages were amplified and their titer determined. The selection was repeated twice using the same steps described above. After the third round of panning the target binding of selected phages was tested by ELISA. After the third round of panning individual clones were picked up from plates and grown in 96-deepwell plates (Eppendorf, Hamburg, Germany). Phages were isolated from the culture supernatant using PEG precipitation. 96-well plates were coated with the target mAbs as in case of the selection.
- the isolated phages were diluted in TBS-T ween and incubated for 1 hour at room temperature in the antibody coated microtiter wells. Bound phages were detected with anti- Mi 3 antibody-horseradish peroxidase conjugate using OPD substrate. Results were scanned with a Victor 2 (PerkinElmer/Wallac, Waltham, MA) microplate reader. ELISA positive clones were selected for DNA sequencing. Phage clones with confirmed binding (ELISA) to the target mAbs were grown in deepwell plates and isolated by PEG precipitation. Single stranded DNA was prepared from them using precipitation with 4 M NaI and ethanol. The sequencing was done by Biomi Ltd.
- EIS epitope redundancy score
- EIS ⁇ (Xi j)/n*m, where Xi,j is the calculated identity score between the ith sequence from the first dataset and the jth sequence from the second dataset; m and n are the number of unique sequences in the two datasets.
- Immunoprecipitation and SDS PAGE electrophoresis was used to specifically precipitate and isolate cognate protein antigens for the mABs. Specific bands were cut from the gels dugested with trypsin and analyzed with MS/MS methodolgy.
- LRR leucine -rich repeat
- Leucine comprises 66 of the 312 amino acids, and LRGl contains at least 8 24-amino acid leucine -rich repeats.
- Increased LRGl expression was detected in GCSF-treated human cells derived from a patient with myeloproliferative disorder. In contrast, decreased LRGl expression was detected after PMA treatment and induction of monocytic differentiation of HL-60 cells.
- LRGl leucine rich alpha-2 glycoprotein
- the invention discloses novel antibodies that recognize specific epitopes in LRGl that represent cancer-specific biomarkers.
- BsiO392 is an IgG type monoclonal antibody.
- the heavy chain variable region amino acid sequence is represented in SEQ ID NO: 92 (see Figure 8), which is reproduced below (CDRs are underlined):
- Fig 9a The difference in biomarker level with BsiO392 is represented Fig 9a, showing a very substantial difference between control and lung cancer.
- BsiO392 recognizes a 4OkDa band in total control plasma samples (see fig 9b).
- fig 9b By mass spectrometry analysis of the antigen, various peptide sequences were obtained (see table below), which demonstrate that BsiO392 binds to LRGl.
- BsiO352 is an IgG type monoclonal antibody.
- the heavy chain variable amino acid sequence is represented in SEQ ID NO: 89 (see figure 8), which is reproduced below (CDRs are underlined):
- biomarker level with BsiO352 is represented Fig 10, showing a very substantial difference between control and lung cancer.
- BsiO352 recognizes a 4OkDa band in total control plasma samples similar to BsiO392.
- mass spectrometry analysis of the antigen various peptide sequences were obtained (see table below), which demonstrate that BsiO352 binds to LRGl .
- YLFLNGNK Peptides bound by BsiO352 have been identified and verified, using either phage display technique or direct Elisa binding. These peptides are presented as SEQ ID NOs: 26-35.
- BsiO351 is an IgG type monoclonal antibody.
- the heavy chain variable amino acid sequence is represented in SEQ ID NO: 88 (see fig 8), reproduced below (CDRs underlined).
- BsiO351 The difference in biomarker level with BsiO351 is represented Fig 11, showing a very substantial difference between control and lung cancer.
- BsiO351 recognizes a 4OkDa band in total control plasma samples similar to BsiO392.
- mass spectrometry analysis of the antigen two peptide sequences were obtained (KDLLLPQPDLRY and RTLDLGENQLETLPPDLLR), which demonstrate that BsiO351 binds to LRGl .
- Bsi358 BsiO358 is an IgG type monoclonal antibody.
- the heavy chain variable amino acid sequence is represented in SEQ ID NO: 90 (see fig 8) reproduced below (CDRs underlined).
- Fig 12a The difference in biomarker level with BsiO358 is represented Fig 12a, showing a very substantial difference between control and lung cancer.
- Western blots with BSI0358 on normal and LC plasma samples before and after depletion of abundant proteins by Agilent depletion columns is represented Fig 12b.
- Molecular mass of reactive band from LC plasma seems to be lower, suggesting that BSI 0358 reacts with a disease-specific form of protein as well.
- Peptides bound by BsiO358 have been identified and verified, using either phage display technique or direct Elisa binding. These peptides are presented as SEQ ID NOs: 1-13.
- BsiO358 can image non small cell lung cancer (NSCLC), as illustrated fig 12c: >90% of NSCLC is positive and 17.6% of SCLC is positive.
- BsiO359 is an IgG type monoclonal antibody.
- the heavy chain variable amino acid sequence is represented in SEQ ID NO: 91 (see fig 8) reproduced below (CDRs)
- VTVSA The difference in biomarker level with BsiO359 is represented Fig 13a, showing a very substantial difference between control and lung cancer.
- BsiO358 BsiO358 alone or in combination, detects a Lung Cancer specific form of the cognate antigen (see Figure 13b).
- BsiO359 binds to purified natural Alpha- 1 -anti chymotrypsin and works in SW assays with antibodies that recognize Alpha- 1 -antichymo trypsin.
- Peptides bound by BsiO359 have been identified and verified, using either phage display technique or direct Elisa binding. These peptides are presented as SEQ ID NOs: 39-42.
- BsiO359 can be used efficiently for cancer histopathology: staining was positive for 84% of NSCLC, 88% adenocarcinoma, 64% squamosus cell carcinoma, and 100% of large cell carcinomas. BsiO359 thus could be useful for imaging.
- Complement factor 9-binding antibodies is a component of the complement system, a multi -protein biochemical cascade which aids to clear pathogens. The cascade is activated upon binding of IgG or IgM to pathogen molecules. C9 is one of the terminal components of the cascade and is responsible for forming pores in target cells leading to their destruction. Deficiencies in complement proteins are believed to be linked to auto-immunity and higher sensitivity to infections.
- the cDNA coding for C9 was sequenced and the protein sequence—537 amino acids in a single polypeptide chain—was derived. The amino -terminal half of C9 is predominantly hydrophilic and the carboxyl-terminal half is more hydrophobic.
- the amphipathic organization of the primary structure is consistent with the known potential of polymerized C9 to penetrate lipid bilayers and cause the formation of transmembrane channels as part of the lytic action of MAC.
- Marazziti et al. (1988) compared gene and protein structure of C9 and compared both with low density lipoprotein receptor (606945).
- the C9 gene is composed of 11 exons with lengths between 100 and 250 bp, except for exon 11 which extends over more than 1 kb, as it includes the 3-prime untranslated region.
- Witzel-Schlomp et al. gave revised information on the structure of the C9 gene, especially the exon-intron boundaries
- C9 has not been associated with cancer of any type.
- the present invention discloses specific antibodies against C9 that can be used as lung cancer biomarkers.
- BsiO272 is an IgG type monoclonal antibody.
- the heavy chain variable amino acid sequence is represented in SEQ ID NO: 86 (see fig 8) reproduced below (CDRs).
- Fig 14a The difference in biomarker level with BsiO272 is represented Fig 14a, showing a very substantial difference between control and lung cancer.
- BsiO272 recognizes a band in total control plasma samples which is compatible to a 559aa polypeptide corresponding to mature C9 polypeptide (Fig 14b).
- Fig 14b By mass spectrometry analysis of the antigen, several peptide sequences were obtained (see table below), which demonstrate that BsiO272 binds to C9.
- Peptides bound by BsiO272 have been identified and verified, using either phage display technique or direct Elisa binding. These peptides are presented as SEQ ID NOs: 14-25.
- BsiO272 stains non small cell lung cancer (NSCLC), as illustrated fig 14c: >74% of NSCLC is positive.
- Haptoglobin (HP), NM 005143 is a tetrameric protein that functions to bind free plasma hemoglobin, thereby allowing degradative enzymes to gain access to the hemoglobin, while at the same time preventing loss of iron through the kidneys and protecting the kidneys from damage by hemoglobin. Mutations in the HP gene and/or its regulatory regions cause ahaptoglobinemia or hypohaptoglobinemia.
- Hp haptoglobin
- Bsi0033 is an IgG type monoclonal antibody.
- the heavy chain variable amino acid sequence is represented in SEQ ID NO: 77 (see fig 8) reproduced below (CDRs underlined).
- Peptides bound by Bsi0033 have also been identified and verified, using either phage display technique or direct Elisa binding. These peptides are presented as SEQ ID NOs: 36- 38.
- Bsi0033 can react with non small cell lung cancer (NSCLC) as well as large cell carcinomas: 81% of NSCLC, 89% adenocarcinoma, 20% squamosus cell carcinoma, and 83% of large cell carcinomas are positive.
- NSCLC non small cell lung cancer
- Bsi0071 is an IgG type monoclonal antibody.
- the heavy chain variable amino acid sequence is represented in SEQ ID NO: 81 (see fig 8) reproduced below (CDRs underlined).
- biomarker level with Bsi0071 is represented Fig 16a, showing a very substantial difference between control and lung cancer.
- Bsi0071 recognizes a band which is consistent with reaction of HP under non-reducing conditions, similar to BsiOO33.
- mass spectrometry analysis of the antigen several peptide sequences were obtained (see table below), which demonstrate that Bsi0071 binds to HP and HRP.
- Complement Factor H (NM OOO 186) is a member of the Regulator of Complement Activation (RCA) gene cluster.
- the CFH protein contains twenty short consensus repeat (SCR) domains, is secreted into the bloodstream, and has an essential role in the regulation of complement activation, restricting this innate defense mechanism to microbial infections. Mutations in this gene have been associated with hemolytic-uremic syndrome (HUS) and chronic hypocomplementemic nephropathy.
- Complement factor H (CFH) is an inhibitor of the alternative complement pathway.
- the present invention discloses specific antibodies against CFH that can be used as lung cancer biomarkers.
- Bsi0077 is an IgG type monoclonal antibody.
- the heavy chain variable amino acid sequence is represented in SEQ ID NO: 83 (see fig 8) reproduced below (CDRs).
- NSCLC non small cell lung cancer
- BsiO271 is an IgG type monoclonal antibody. Antigen binding was determined by western blot and MS analysis. By mass spectrometry analysis of the antigen, several peptide sequences were obtained (see table below), which demonstrate that Bsi0077 binds to CFH.
- R.TGESVEFVCK.R Peptides bound by BsiO271 have been identified and verified, using either phage display technique or direct Elisa binding. These peptides are presented as SEQ ID NOs: 43-56.
- Bsi0077 can image non small cell lung cancer (NSCLC) as well as carcinomas: 81% of NSCLC, 84% adenocarcinoma, 60% squamous cell carcinoma, and 67% of large cell carcinomas were positive.
- NSCLC non small cell lung cancer
- the best linear model was calculated using leave-one out cross-validation on a training set, and the accuracy was estimated on a test set of independent samples.
- the accuracy of the 1013 combinations is plotted as a histogram where the number of panels with specific accuracy is reported on the y-axis (see Fig 18). The number of the occurrences of each antibody in the panels with accuracy higher than 0.8 is plotted on the y-axis.
- the optimal threshold (0.115) was calculated from the logistic regression model to provide the optimum combination of sensitivity (80.4%) and specificity (86.2 %).
- the performance of this classifier to predict patients with different stages of the disease show that its performance increases with the stage of the disease, and even at stage I the sensitivity is 77.3%. Slightly better performance of the classifier should be also noted for patients with squamous cell carcinoma (Table II).
- Adenocarcinoma 66 (85) 77.6 %
- ROC curves are presented in Figure 20 where panels are numbered from 1-10 based on this table.
- the results show the antibodies of the invention differentiate control and lung cancer, either alone or in combinations. These antibodies allow the design of efficient diagnostic products (e.g., devices, kits) to detect, monitor or image cancer in human subjects.
- the epitope redundancy is expressed as percentage of identical residues in the aligned set of peptide sequences between two antibodies (see Methods).
- the functional redundancy is expressed as the adjusted chi-square of fitting the correlation of the responses of two antibodies with the 610 clinical samples measured in the HT-ELISA screening to a linear function (see
- Peptides bound by further antibodies of the invention are Peptides bound by further antibodies of the invention. % represent peptide sequence occurrence in the tested group.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23105109P | 2009-08-04 | 2009-08-04 | |
US28974509P | 2009-12-23 | 2009-12-23 | |
PCT/EP2010/061354 WO2011015602A2 (en) | 2009-08-04 | 2010-08-04 | Lung cancer biomarkers |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2462164A2 true EP2462164A2 (en) | 2012-06-13 |
Family
ID=42951214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10739934A Ceased EP2462164A2 (en) | 2009-08-04 | 2010-08-04 | Lung cancer biomarkers |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2462164A2 (en) |
CA (1) | CA2769406A1 (en) |
WO (1) | WO2011015602A2 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0915515D0 (en) | 2009-09-04 | 2009-10-07 | Ucl Business Plc | Treatment of vasculoproliferative conditions |
US9701742B2 (en) * | 2011-07-01 | 2017-07-11 | The Trustees Of The University Of Pennsylvania | Anti-properdin antibodies and uses thereof |
WO2013132267A1 (en) * | 2012-03-09 | 2013-09-12 | Ucl Business Plc | Treatment of cancer |
WO2014055835A1 (en) | 2012-10-04 | 2014-04-10 | Novelmed Therapeutics, Inc. | Alternative pathway specific antibodies for treating hemolytic diseases |
CN103926413A (en) * | 2014-04-28 | 2014-07-16 | 刘红莉 | Preparation method of reagent strip for quickly detecting cancer by utilizing urea |
GB201503438D0 (en) | 2015-02-27 | 2015-04-15 | Ucl Business Plc | Antibodies |
CN108026584B (en) * | 2015-09-11 | 2021-12-10 | 适体科学株式会社 | Protein biomarker panel for diagnosing non-small cell lung cancer and non-small cell lung cancer diagnosis method using same |
CN107356761B (en) * | 2016-05-09 | 2020-03-31 | 上海华盈生物医药科技有限公司 | Use of elderberry agglutinin and haptoglobin-related protein |
GB201702792D0 (en) | 2017-02-21 | 2017-04-05 | Queens Univ Of Belfast | A new biomarker for preeclampsia |
EP3676393A4 (en) | 2017-09-01 | 2021-10-13 | Venn Biosciences Corporation | Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring |
EP3798227A4 (en) * | 2018-05-09 | 2022-03-02 | Good T Cells, Inc. | Epitope of regulatory t cell surface antigen and antibody specifically binding thereto |
JP7421712B2 (en) * | 2018-10-09 | 2024-01-25 | 積水メディカル株式会社 | Leucine-rich α2 glycoprotein composition |
EP3671210A1 (en) * | 2018-12-21 | 2020-06-24 | Biosystems International KFT | Lung cancer protein epitomic biomarkers |
JP2023519969A (en) * | 2020-03-31 | 2023-05-15 | シアトル・チルドレンズ・ホスピタル・ドゥーイング/ビジネス/アズ・シアトル・チルドレンズ・リサーチ・インスティテュート | Proteomics screening for lysosomal storage diseases |
WO2024050524A1 (en) * | 2022-09-01 | 2024-03-07 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
JPS5441129A (en) | 1977-09-07 | 1979-04-02 | Minolta Camera Co Ltd | Modified gauss type photographic lens |
FR2724182B1 (en) | 1994-09-02 | 1996-12-13 | Pasteur Institut | OBTAINING A RECOMBINANT MONOCLONAL ANTIBODY FROM A HUMAN ANTI-RHESUS D MONOCLONAL ANTIBODY, ITS PRODUCTION IN INSECT CELLS, AND USES THEREOF |
US20070099251A1 (en) * | 2005-10-17 | 2007-05-03 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
US7416850B2 (en) * | 2006-01-25 | 2008-08-26 | Jemmerson Ronald R | Cytochrome c and leucine-rich alpha-2-glycoprotein-1 assays, methods and antibodies |
KR100846354B1 (en) * | 2007-03-21 | 2008-07-15 | (주) 프로탄바이오 | Diagnostic biomarker for lung adenocarcinoma isolated from serum glycoproteins |
-
2010
- 2010-08-04 EP EP10739934A patent/EP2462164A2/en not_active Ceased
- 2010-08-04 WO PCT/EP2010/061354 patent/WO2011015602A2/en active Application Filing
- 2010-08-04 CA CA2769406A patent/CA2769406A1/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
M. GUERGOVA-KURAS ET AL: "Discovery of Lung Cancer Biomarkers by Profiling the Plasma Proteome with Monoclonal Antibody Libraries", MOLECULAR & CELLULAR PROTEOMICS, vol. 10, no. 12, 26 September 2011 (2011-09-26), pages M111.010298 - M111.01029, XP055026003, ISSN: 1535-9476, DOI: 10.1074/mcp.M111.010298 * |
See also references of WO2011015602A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2011015602A3 (en) | 2011-05-26 |
WO2011015602A2 (en) | 2011-02-10 |
CA2769406A1 (en) | 2011-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011015602A2 (en) | Lung cancer biomarkers | |
JP6029218B2 (en) | Lung cancer differentiation marker | |
DK3054298T3 (en) | METHOD OF DETECTING TUMOR IN THE ARC | |
Jiang et al. | Peptide mimic isolated by autoantibody reveals human arrest defective 1 overexpression is associated with poor prognosis for colon cancer patients | |
EP2668503B1 (en) | Combinatorial biomarkers for clinical applications in lung cancer patient management | |
US20180224455A1 (en) | Using phage epitopes to profile the immune response | |
JP6276992B2 (en) | Molecular markers for early detection of pleural mesothelioma patients and their expression analysis methods | |
KR20180041467A (en) | Immunoassay using antibody specifically binding to core fucosylated alpha-fetoprotein | |
EP2620772A1 (en) | Gastric cancer biomarkers and methods of use thereof | |
US20210318316A1 (en) | Lung cancer protein epitomic biomarkers | |
WO2013187371A1 (en) | Method for detecting cancer, and antibody capable of recognizing pancreas-specific ribonuclease 1 | |
CN111303289B (en) | Anti-human Tn-type glycosylated MUC1 antibody and application thereof | |
EP2541249A1 (en) | EpCAM detection | |
JP6760562B2 (en) | Information provision method for predicting the prognosis of patients with clear cell ovarian cancer | |
JP6244644B2 (en) | Pancreatic cancer detection method and detection kit | |
US20240117070A1 (en) | Recombinant antibodies, kits comprising the same, and uses thereof | |
KR102131860B1 (en) | Biomarker Composition for Diagnosing Colorectal Cancer Specifically Binding to Arginine-methylated Gamma-glutamyl Transferase 1 | |
WO2020218121A1 (en) | Cancer detection method and detection reagent | |
KR20180041466A (en) | Antibody specifically binding to core fucosylated alpha-fetoprotein and use thereof | |
GUERGOVA-KURAS et al. | LLLLLGGG GGGGGGGG LLLLL GGGGGGGG | |
KR101848409B1 (en) | Monoclonal Antibody Against Lung Cancer Specific Protein Marker Haptoglobin and Composition for Disgnosing Lung Cancer Comprising the Same | |
CN115698718A (en) | Method and reagent for detecting pancreatic cancer | |
KR20220122965A (en) | Recombinant peptides binding to tumor-specific antibodies against breast cancer and uses | |
JP2014115199A (en) | Method for detecting stomach cancer or esophagus cancer | |
JP2014167419A (en) | Combination of molecular markers for early detection of pleural mesothelioma patient and method for analyzing expression of molecular markers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20120120 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20130107 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: F. HOFFMANN-LA ROCHE SA |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20170127 |